Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 19/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 2/20 | 0.50 |
| ▸ | HTR7 | P34969 | 2/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.50 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8021905 | 0.90 | HTR6 (0.82) | HTR6ADRA2ADRD2HTR2AHTR2C | |
| SCHEMBL12868529 | 0.88 | HTR6 (0.78) | HTR6ADRA2ADRD2HTR2AHTR2C | |
| SCHEMBL8033750 | 0.85 | HTR6 (0.74) | HTR6HDAC1HDAC2HDAC6 | |
| SCHEMBL801073 | 0.84 | HTR6 (1.00) | HTR6ADRA2ADRD2HTR2AHTR2C | |
| SCHEMBL12868943 | 0.84 | HTR6 (0.72) | HTR6ADRA2ADRD2HTR2AHTR2C | |
| SCHEMBL8021900 | 0.81 | HTR6 (0.68) | HTR6ADRA2AADRA1AHRH1HDAC1 | |
| SCHEMBL8036424 | 0.81 | HTR6 (0.68) | HTR6ADRA2ADRD2HTR2AHTR2C | |
| SCHEMBL12868164 | 0.81 | HTR6 (0.67) | HTR6ADRA2ADRD2HTR2AHTR2C | |
| SCHEMBL12868160 | 0.78 | HTR6 (0.64) | HTR6ADRA2ADRD2HTR2AHTR2C | |
| SCHEMBL13142066 | 0.77 | HTR6 (0.63) | HTR6ADRA2AHTR2AHTR2CHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2433939-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | Alla Chem, LLC. (US) | 2012-03-28 | — | — | EP | disclosed |
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | IVASHCHENKO ANDREY ALEXANDROVICH (RU) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071493-A1 | SUBSTITUTED 8-SULFONYL-2,3,4,5-TETRAHYDRO-1H-GAMMA-CARBOLINES, LIGANDS AND PHARMACEUTICAL COMPOSITION; METHOD FOR THE PRODUCTION AND USE OF SAME | SIGMAR1, ADRA2C, ADRB2 | HTR6 69/4885ADRA2A 10/4885DRD2 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.